Lv41
470 积分 2024-10-30 加入
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
21天前
已完结
Transforming TGF-β suppression into IL-15 stimulation: Advancing engineered CAR-T therapy for solid tumors
1个月前
已完结
806MO Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)
1个月前
已关闭
CAR T cell combination therapies to treat cancer
2个月前
已完结
Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment
2个月前
已完结
Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion
3个月前
已完结
Abstract LB090: IL-18 secreting chimeric antigen receptor T cells targeting glypican-3show superior persistence and antitumor immunity against hepatocellular carcinoma
3个月前
已关闭
TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
4个月前
已完结
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
4个月前
已完结
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
4个月前
已完结
皖公网安备34019202002308
